"Patrick Neven, MD, PhD Universitaire Ziekenhuizen Leuven, Belgium 5Live #ASCO20"
4:58
Key Insights on MONARCH 2: subgroup analysis of pts receiving abemaciclib + fulvestrant as first- and second-line therapy for HR+, HER2- advanced BC
Breast Cancer
"Patrick Neven, MD, PhD Universitaire Ziekenhuizen Leuven, Belgium 5Live #ASCO20"
Key Insights on MONARCH 2: subgroup analysis of pts receiving abemaciclib + fulvestrant as first- and second-line therapy for HR+, HER2- advanced BC
Breast Cancer Similar Videos
Similar Videos
-
Building Health Equity and Multidirectional Trust in Cancer Care_Breast & Colorectal Cancer_Lisa Newman, MD, MPH, FACS, FASCO, FSSO_Laura Musselwhite, MD, MPH
50:13
-
Mylin Torres, MD; Emory University Winship Cancer Institute; #DDHO2022
19:43
-
Manali Bhave, MD; Emory University Winship Cancer Institute; #DDHO2022
15:09
